Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ligand PharmaceuticalsFRA:LGDN 76 3-1 Month Momentum % is 45.36% as of Aug. 14, 2026. GuruFocus rates FRA:LGDN with a GF Score™ of 76/100 and a GF Value™ of €153.58 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,388 Biotechnology companies, Ligand Pharmaceuticals ranks better than 94.31% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-14), Ligand Pharmaceuticals's 3-1 Month Momentum % is 45.36%.
The industry rank for Ligand Pharmaceuticals's 3-1 Month Momentum % or its related term are showing as below:
FRA:LGDN's 3-1 Month Momentum % is ranked better than 94.31% of 1388
companies
in the Biotechnology industry
Industry Median: -8.13
vs FRA:LGDN: 45.36
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Ligand Pharmaceuticals 3-1 Month Momentum % Related Terms
FRA:LGDN vs CGON, DFTX, XENE: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Ligand Pharmaceuticals's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ligand Pharmaceuticals 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ligand Pharmaceuticals's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Ligand Pharmaceuticals's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ligand Pharmaceuticals (FRA:LGDN) has a 3-1 Month Momentum % of 45.36% as of Aug. 14, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ligand Pharmaceuticals and its competitors. According to the industry distribution chart, Ligand Pharmaceuticals ranks #79 out of 1388 companies in the Biotechnology industry, placing it in the top 5.7%.
Is Ligand Pharmaceuticals' 3-1 Month Momentum % too high?
Ligand Pharmaceuticals' current 3-1 Month Momentum % is 45.36%. Based on the distribution chart, Ligand Pharmaceuticals ranks #79 out of 1388 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ligand Pharmaceuticals has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ligand Pharmaceuticals' 3-1 Month Momentum % compare to CGON and DFTX?
According to the Biotechnology industry distribution chart, Ligand Pharmaceuticals ranks #79 out of 1388 companies for 3-1 Month Momentum %. This places Ligand Pharmaceuticals in the top 6% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ligand Pharmaceuticals and its competitors. Ligand Pharmaceuticals's current 3-1 Month Momentum % is 45.36%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ligand Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ligand Pharmaceuticals (FRA:LGDN) is currently considered Significantly Overvalued. The stock's GF Value™ is €153.58, compared to a current price of €246.00 — trading 60.2% above its estimated fair value. The current 3-1 Month Momentum % is 45.36%. Ligand Pharmaceuticals' overall GF Score™ is 76/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Ligand Pharmaceuticals (FRA:LGDN), the current 3-1 Month Momentum % is 45.36% as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ligand Pharmaceuticals (FRA:LGDN) Overvalued in 2026?
Based on GuruFocus' analysis, Ligand Pharmaceuticals stock appears to be overvalued.
The current stock price of €246.00 is trading 60.2% above its estimated GF Value™ of €153.58.
GuruFocus considers Ligand Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:LGDN:
3-1 Month Momentum %: 45.36%
GF Value™: €153.58 vs. price of €246.00 (60.2% above fair value)
No single metric tells the full story. See the FRA:LGDN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
76GF Score
Get the complete analysis for FRA:LGDN
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LGDN has been successfully added to your 
